Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817095) titled 'SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
Undifferentiated Pleomorphic Sarcoma (UPS)
Intervention:
Drug: Toripalimab
Drug: Liposomal doxorubicin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 2026
...